Afatinib versus placebo as adjuvant therapy after chemoradiation in a double-blind, phase III study (LUX-Head & Neck 2) in patients with primary unresected, clinically intermediate-to-high-risk head and neck cancer: study protocol for a randomized controlled trial

Barbara Burtness; Jean P Bourhis; Jan B Vermorken; Kevin J Harrington; Ezra EW Cohen

首页> 外文期刊>Trials >Afatinib versus placebo as adjuvant therapy after chemoradiation in a double-blind, phase III study (LUX-Head & Neck 2) in patients with primary unresected, clinically intermediate-to-high-risk head and neck cancer: study protocol for a randomized controlled trial

【24h】

Afatinib versus placebo as adjuvant therapy after chemoradiation in a double-blind, phase III study (LUX-Head & Neck 2) in patients with primary unresected, clinically intermediate-to-high-risk head and neck cancer: study protocol for a randomized controlled trial

机译：在一项双盲，III期临床研究（LUX-Head＆Neck 2）中，对患有原发性未切除，临床中度至高风险的头颈癌患者进行化学放疗后，阿法替尼与安慰剂作为辅助疗法：随机对照研究方案试用

获取原文

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Trials》 |2014年第1期|共页
作者
Barbara Burtness; Jean P Bourhis; Jan B Vermorken; Kevin J Harrington; Ezra EW Cohen;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类自然科学研究方法;
关键词

相似文献

外文文献

1. Rationale and design of LUX-Head & Neck 1: a randomised, Phase III trial of afatinib versus methotrexate in patients with recurrent and/or metastatic head and neck squamous cell carcinoma who progressed after platinum-based therapy [J] . Jean-Pascal H Machiels, Lisa F Licitra, Robert I Haddad, BMC Cancer . 2014,第1期

机译：LUX-Head＆Neck的原理和设计1：阿法替尼与甲氨蝶呤在铂类药物治疗后复发和/或转移性头颈部鳞状细胞癌患者中进行的一项随机，III期临床试验
2. Rationale and design of LUX-Head & Neck 1: a randomised, Phase III trial of afatinib versus methotrexate in patients with recurrent and/or metastatic head and neck squamous cell carcinoma who progressed after platinum-based therapy [J] . Jean-Pascal H Machiels, Lisa F Licitra, Robert I Haddad, BMC Cancer . 2014,第1期

机译：LUX-Head＆Neck的原理和设计1：阿法替尼与甲氨蝶呤在铂类药物治疗后复发和/或转移性头颈部鳞状细胞癌患者中进行的一项随机，III期临床试验
3. Postoperative Adjuvant Lapatinib and Concurrent Chemoradiotherapy Followed by Maintenance Lapatinib Monotherapy in High-Risk Patients With Resected Squamous Cell Carcinoma of the Head and Neck: A Phase III, Randomized, Double-Blind, Placebo-Controlled Study [J] . Harrington Kevin, Temam Stephane, Mehanna Hisham, Journal of Clinical Oncology . 2015,第35期

机译：高风险患者头颈部鳞状细胞癌切除术后术后辅助用拉帕替尼和同期放化疗联合维持拉帕替尼单药治疗：III期，随机，双盲，安慰剂对照研究
4. EFFECT OF TARGETED PULSED ELECTROMAGNETIC FIELD THERAPY ON CANINE POST-OPERATIVE HEMILAMINECTOMY: A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED CLINICAL TRIAL [C] . ACVS Veterinary Symposium . 2018

机译：靶向脉冲电磁场治疗对犬术后血栓切除术的影响：双盲，随机，安慰剂对照临床试验
5. Evaluation of a randomized clinical trial of a psychoeducational intervention on long-term quality of life, negative affect, progression and survival in head and neck cancer patients. [D] . Trevino, Lara A. 2011

机译：心理教育干预对头颈部癌症患者的长期生活质量，负面影响，进展和生存的随机临床试验评估。
6. Afatinib versus placebo as adjuvant therapy after chemoradiation in a double-blind phase III study (LUX-Head Neck 2) in patients with primary unresected clinically intermediate-to-high-risk head and neck cancer: study protocol for a randomized controlled trial [O] . Barbara Burtness, Jean P Bourhis, Jan B Vermorken, 2014

机译：在一项双盲III期临床研究（LUX-Head＆Neck 2）中对患有原发性未切除临床中度至高风险的头颈部癌症患者进行化学放疗后阿法替尼与安慰剂作为辅助疗法：随机对照研究方案试用
7. Afatinib versus placebo as adjuvant therapy after chemoradiation in a double-blind, phase III study (LUX-Head & Neck 2) in patients with primary unresected, clinically intermediate-to-high-risk head and neck cancer: study protocol for a randomized controlled trial. [O] . Burtness, B., Bourhis, J.P., Vermorken, J.B., 2014

机译：在一项双盲，III期临床研究（LUX-Head＆Neck 2）中，对患有原发性未切除，临床中度至高风险的头颈癌患者进行化学放疗后，阿法替尼与安慰剂作为辅助疗法：随机对照研究方案试用。

Afatinib versus placebo as adjuvant therapy after chemoradiation in a double-blind, phase III study (LUX-Head & Neck 2) in patients with primary unresected, clinically intermediate-to-high-risk head and neck cancer: study protocol for a randomized controlled trial

著录项

相似文献

相关主题

期刊订阅